00:58:44 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Halvårsutdelning VISTN 0.5
2024-10-31 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-06-05 Halvårsutdelning VISTN 0.5
2024-05-23 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2024-01-23 Ordinarie utdelning VISTN 0.75 NOK
2023-10-25 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-23 Ordinarie utdelning VISTN 0.00 NOK
2023-05-22 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-24 Ordinarie utdelning VISTN 0.00 NOK
2022-05-19 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-28 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-21 Ordinarie utdelning VISTN 0.50 NOK
2021-05-20 Årsstämma 2021
2021-04-23 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-10-30 Kvartalsrapport 2020-Q3
2020-08-28 Kvartalsrapport 2020-Q2
2020-06-24 Extra Bolagsstämma 2020
2020-05-20 Ordinarie utdelning VISTN 1.00 NOK
2020-05-19 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-10-25 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning VISTN 0.00 NOK
2019-05-22 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-02-19 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-08-30 Kvartalsrapport 2018-Q2
2018-05-25 Ordinarie utdelning VISTN 1.00 NOK
2018-05-08 Årsstämma 2018
2018-04-26 Kvartalsrapport 2018-Q1
2018-02-27 Bokslutskommuniké 2017
2017-11-03 Bonusutdelning VISTN 7
2017-11-02 Extra Bolagsstämma 2017
2017-10-27 Kvartalsrapport 2017-Q3
2017-08-31 Kvartalsrapport 2017-Q2
2017-05-26 Ordinarie utdelning VISTN 1.00 NOK
2017-05-24 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-10-31 Kvartalsrapport 2016-Q3
2016-08-30 Kvartalsrapport 2016-Q2
2016-05-25 Ordinarie utdelning VISTN 0.60 NOK
2016-05-24 Årsstämma 2016
2016-04-28 Kvartalsrapport 2016-Q1
2016-02-23 Bokslutskommuniké 2015
2015-10-29 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriLäkemedel & Handel
Vistin Pharma är ett norskt läkemedelsbolag. Bolaget bedriver forskning och utveckling samt vidare produktion av farmaceutiska substanser (API), främst substanserna metformin, kodein fosfat och folkodin. Substanserna används huvudsakligen vid behandling av diabetes. Idag innehas verksamhet på global nivå, med störst närvaro på den nordiska marknaden. Vistin Pharma grundades under 2015 och har sitt huvudkontor i Oslo.
2022-08-19 07:50:00

Oslo, Norway, 19th of August 2022

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) today announces the financial results for the second quarter 2022

Revenue in second quarter ended at MNOK 69 compared to MNOK 67 in Q2 2021, a 3% increase. Sales volume in quarter down by approx. 11% compared to Q2’21, due to limited sales volume available.

Second quarter EBITDA ended at MNOK 4.7 (Q2’21: MNOK 13.4). EBITDA unfavorably affected by limited sales volume available, start-up costs for new line, FX and record high electricity prices in quarter. Financial result expected to continue to improve in coming quarters, with more volumes available for sale.

The net profit ended at MNOK 0.2 (Q2’21: MNOK 8.1) for the second quarter of 2022.

Production line #1 has been producing according to plan in quarter, however at slightly reduced capacity due to a 5-day planned maintenance stop and optimization of production with two lines. New line #2 has been producing at reduced capacity as part of volume ramp-up phase. Capacity is expected to ramp-up gradually during Q3 and Q4 and reach an annual capacity rate of >5 500MT by end 2022. Annual capacity of approx. 7 000MT expected to be reached during 2023.

Vistin Pharma had net debt of MNOK 35 (Q2’21 net cash MNOK: 60) as of 30 June 2022. Driven by volume-ramp up there has been a significant increase in working capital requirements in 1H’22 driven by raw material stock and time from production start of line #2 to payment from customers. Cash flow expected to improve from Q4. A revolving credit facility has been established to handle planned liquidity effects from ongoing expansion and investments.

Approx. 80% of the Metformin Expansion Project (MEP) has been paid as of end June and project cost is according to budget. The company has a strong balance sheet with an equity ratio of 70%.

The second quarter conference call, which will be held today, 19th of August, at 8.30am (CET), will be available via webcast and audio through the following access points:

Webcast:
https://edge.media-server.com/mmc/p/m83myj4s

Telephone conference (online registration):

https://register.vevent.com/register/BI3e5ac1165d974dacab56dd8f81b4fba4

The conference call will be held in English.    

Please find the Q2 report and presentation enclosed. The report will also be made available on www.vistin.com.

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.